BVF Partners and RA Capital Management completed a $65m investment in Concert Pharmaceuticals.

BVF Partners, a San Francisco-based investment firm specializing in biotechnology and healthcare, and RA Capital Management, a multi-stage investment firm, completed a $65m investment in Concert Pharmaceuticals, a clinical-stage biopharmaceutical company. Pursuant to this financing, BVF and RA will also receive a portion of potential future AVP-786 royalties currently payable to Concert by Avanir. AVP-786 is currently being evaluated in a number of clinical trials, including Phase 3 trials for the treatment of agitation in patients with dementia of the Alzheimer’s type.